StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Heron Therapeutics to Sell Nearly All Assets to CorMedix for $145 Million

Heron Therapeutics agreed to sell substantially all its assets to CorMedix for $145 million in cash plus stock, royalties and earn-outs, while retaining its tax-loss carryforwards; shares closed up 27.6% on 65 times average volume.

What happened

Heron Therapeutics, Inc., a Delaware corporation based in Cary, North Carolina, disclosed in a Form 8-K filed November 9, 2026 that it entered into an Asset Purchase Agreement on November 8, 2026 with CorMedix Inc., also a Delaware corporation, to sell substantially all of its assets to CorMedix.

Heron is a pharmaceutical company that markets injectable products for chemotherapy-induced nausea and vomiting and for post-operative pain. Its products named in the filing are CINVANTI, SUSTOL and ZYNRELEF; the filing also refers to a multi-product Development and License Agreement.

Under the agreement, CorMedix will issue 14,583,333 shares of its common stock to Heron and pay $145.0 million in cash, subject to adjustments for Heron's closing cash and net working capital. Of that cash, $2.0 million will be placed in escrow with Citibank, N.A. at closing to secure post-closing adjustments, which the filing says may not exceed $10.0 million in either direction.

Heron will also receive royalties equal to 5.0% of the amount by which aggregate annual net sales of CINVANTI, SUSTOL and the products covered by the Development and License Agreement exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable. It will receive earn-out payments of $25.0 million if ZYNRELEF net sales for calendar year 2028 equal or exceed $65.0 million, plus another $30.0 million if those sales equal or exceed $95.0 million. CorMedix may pay the earn-outs in cash, stock or a combination, but any portion that would push total shares issued under the agreement above 19.9% of CorMedix's outstanding common stock at closing must be paid in cash.

Heron said it does not intend to liquidate after closing. It plans to use part of the net proceeds to repay all amounts outstanding under its Working Capital Facility Agreement dated August 9, 2023 with Hercules Capital, Inc. as administrative and collateral agent and the lenders party to it, as amended. Heron will retain the CorMedix shares it receives, the right to future royalties and earn-outs, significant net operating loss carryforwards (NOLs) and other tax attributes, and cash on hand.

Heron's board unanimously approved the agreement and agreed to recommend that stockholders approve it. The transaction requires approval by holders of a majority of Heron's outstanding common stock. No vote of CorMedix stockholders is required. CorMedix's obligation is not subject to any financing condition.

The agreement includes a customary no-solicitation covenant, subject to exceptions for unsolicited proposals. Heron may change its board recommendation in response to a superior proposal under specified conditions, and may terminate to accept a superior proposal if it pays a $4.0 million termination fee. The agreement also sets an outside date of six months after signing and cross-licensing covenants: Heron is barred for five years from competing worldwide in injectable aprepitant or granisetron products for chemotherapy-induced or post-operative nausea and vomiting, and in non-opioid anesthetics containing bupivacaine or low-dose meloxicam for post-operative pain, with certain exceptions. Each party also agreed to a three-year non-solicitation covenant covering the other's employees, subject to exceptions.

The other agreements in the filing

The 8-K also discloses Amendment No. 2 to Heron's Tax Benefit Preservation Plan dated November 8, 2026, signed before the purchase agreement and related agreements. The plan, originally dated August 14, 2025 and ratified by stockholders on June 11, 2026, was adopted to protect against a possible limitation on Heron's ability to use its NOLs and other tax attributes to reduce future federal income taxes. Amendment No. 1, dated August 13, 2026, extended the plan's final expiration date to August 14, 2029.

The new amendment carves out an exception to the plan's "Acquiring Person" definition: no person will become an Acquiring Person as a result of an agreement giving that person the right to acquire, vote or dispose of, or otherwise beneficially own, Heron common stock, if the agreement was executed by Heron and approved by the board for that exception before the person would otherwise become an Acquiring Person. It also amends the plan so that, upon a merger, acquisition or similar transaction, the plan and its rights terminate only if the board approves termination; without that approval, the plan continues after closing.

The filing also states that Heron and CorMedix entered into separate Voting and Support Agreements with funds managed by Rubric Capital Management LP and Velan Capital Investment Management LP, and with each of Heron's directors and executive officers. The text provided is cut off at that point and does not describe the terms of the voting agreements.

Price and volume

Heron shares closed at $0.37 on the event date, up 27.59% from a prior close of $0.29, according to the price data. Volume was 138,629,300 shares against an average of 2,132,490, a multiple of 65.01 times average.

What this means

An 8-K is the current report a US public company files with the Securities and Exchange Commission to disclose material events to investors. The item numbers in this filing map to what was disclosed: Item 1.01 covers entry into a material definitive agreement, Item 3.03 covers a material modification to the rights of security holders, Item 7.01 is a Regulation FD disclosure made to the market broadly, and Item 9.01 covers exhibits.

The primary transaction is an asset sale, not a merger. Heron is selling the business itself — its products, the related agreements and other operating assets — rather than having CorMedix buy Heron's shares. Heron remains a public company listed on the Nasdaq Capital Market under the ticker HRTX, but after closing it would hold a portfolio of cash, CorMedix stock, royalty and earn-out rights, and tax assets, rather than an operating pharmaceutical business. The filing says the board intends to evaluate strategic transactions for the proceeds, possibly including acquisitions or investments that may or may not be in pharmaceutical or biotechnology businesses.

The NOLs explain several unusual features. A net operating loss carryforward is a tax asset: past losses that can be used to offset future taxable income and reduce future federal income taxes. Their value depends on a company being able to use them before they expire, and US tax rules limit how much of an NOL a new owner can use after an ownership change. Heron is keeping its NOLs rather than selling them, and the tax benefit preservation plan is designed to deter investors from accumulating enough stock to trigger those limitation rules. The plan amendment giving the board control over whether the plan terminates after a transaction is another attempt to keep that protection in place.

The earn-outs and royalties are contingent payments: they are owed only if defined sales thresholds are met in specified future years. The 19.9% cap on CorMedix stock issued under the agreement is a common structural limit; the filing states that any earn-out portion exceeding it must be paid in cash.

The next formal step is a Heron stockholder vote, which the filing says is required for the transaction to close. Other closing conditions include expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, listing approval on the Nasdaq Global Market for the CorMedix shares issued as consideration, accuracy of each party's representations and warranties, performance of covenants and absence of a material adverse effect, and no injunction or legal prohibition blocking the sale. The agreement can be terminated if closing has not occurred by the date six months after signing.

The 5% royalty, the two ZYNRELEF sales thresholds and the $4.0 million termination fee are set out in the purchase agreement as filed. The filing does not state how the parties arrived at these specific terms, and it does not give a reason for the price reaction or volume.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.